Investing in Transformative Companies

Aescap has two investment funds that invest in publicly traded biotech / life sciences companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics. The funds operate under a full AIFM license and are managed by an experienced team with a great track record. Read how the funds generate good financial returns and in parallel impact the daily lives of millions of people. The name Aescap is derived from Aesculapius, the Roman god of Medicine, and “Capital”.

Biotech market

The biotech sector, also known as the life sciences sector, is a large and fast-growing sector driven on the one hand by a globally aging population and the need for western medicine in emerging markets. On the other hand, the biotech sector is driven by innovation which has taken big leaps in recent years in areas such as RNA, gene and cell therapies. With around 1000 public biotech companies it requires quite some expertise to navigate the investment landscape and find derisked companies with a high earning power that are still undervalued.

Get acquainted

Our monthly presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on January 26th at 15.00 CET.

Meet the investment team

The Aescap investment team, led by Portfolio Manager Patrick Krol, consists of experienced professionals with different backgrounds playing an essential role in the performance of the biotech funds. The team manages a portfolio of successful biotech companies that not only provide a good financial return but contribute to improving the well-being of patients through their groundbreaking medicine.

Subscribe to our newsletter here.

    Latest news

    Aescap Life Sciences Quarterly Update Q4 2021

    The Year in Review and What is Coming Up. Looking back at 2021 we saw sharp declining biotech share prices as of mid-February 2021 around the so-called ‘Turn out of Tech’.

    Portfolio News – Acquisition of Portfolio Company Dicerna – Nov 18, 2021

    Portfolio company Dicerna Pharmaceuticals announced that it has entered into a definitive agreement with pharma company Novo Nordisk under which Novo Nordisk will acquire Dicerna for $ 38,25 per share and a total equity value of $ 3,3 billion, representing an 80% premium compared to Dicerna’s share price at closing on Nov 17, 2021.

    Facts & Figures – From History to Future in Cancer Treatment

    At the beginning of the 20th century, the only two options doctors had available to treat cancer were surgery and/or radiation therapy. At that time, cancers that couldn’t be removed or irradiated, because of their position or because they involved blood cells, were deemed untreatable.